Fortrea Holdings Inc. (FTRE)
| Market Cap | 1.46B +176.2% |
| Revenue (ttm) | 2.71B +0.9% |
| Net Income | -446.90M |
| EPS | -4.85 |
| Shares Out | 94.60M |
| PE Ratio | n/a |
| Forward PE | 18.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,391,409 |
| Open | 15.59 |
| Previous Close | 15.57 |
| Day's Range | 14.71 - 15.61 |
| 52-Week Range | 3.97 - 18.67 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 14.50 (-6.03%) |
| Earnings Date | May 5, 2026 |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, ... [Read more]
Financial Performance
In 2025, Fortrea Holdings's revenue was $2.72 billion, an increase of 1.00% compared to the previous year's $2.70 billion. Losses were -$986.20 million, 200.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price target is $14.5, which is a decrease of -6.03% from the latest price.
News
Fortrea price target raised to $14 from $11 at Deutsche Bank
Deutsche Bank analyst Justin Bowers raised the firm’s price target on Fortrea (FTRE) to $14 from $11 and keeps a Hold rating on the shares.
Fortrea price target raised to $16 from $11 at Barclays
Barclays raised the firm’s price target on Fortrea (FTRE) to $16 from $11 and keeps an Equal Weight rating on the shares.
Fortrea price target raised to $20 from $15 at Baird
Baird raised the firm’s price target on Fortrea (FTRE) to $20 from $15 and keeps an Outperform rating on the shares.
Fortrea price target raised to $20 from $15 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Fortrea (FTRE) to $20 from $15 and keeps an Outperform rating on the shares.
Fortrea price target raised to $20 from $16 at Citi
Citi raised the firm’s price target on Fortrea (FTRE) to $20 from $16 and keeps a Buy rating on the shares.
Fortrea price target raised to $18 from $15 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Fortrea (FTRE) to $18 from $15 and keeps a Buy rating on the shares. The firm said its beat
Fortrea price target raised to $19 from $16 at Truist
Truist raised the firm’s price target on Fortrea (FTRE) to $19 from $16 and keeps a Buy rating on the shares. The firm is updating its model after holding talks
Fortrea Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw strong commercial momentum, margin expansion, and improved operational efficiency, with a book-to-bill of 1.15x and significant gains in biotech and China. Revenue declined 2.3% year-over-year, but adjusted EBITDA and net income improved, supporting reaffirmed full-year guidance.
Fortrea Reports First Quarter 2026 Results
Strong first-quarter performance reinforces confidence in FY 2026 guidance Book-to-bill of 1.15x is third consecutive quarter above 1.1x
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2...
Fortrea price target lowered to $11 from $12 at Barclays
Barclays lowered the firm’s price target on Fortrea (FTRE) to $11 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science
Fortrea price target lowered to $14 from $25 at Evercore ISI
Evercore ISI lowered the firm’s price target on Fortrea (FTRE) to $14 from $25 and keeps an Outperform rating on the shares. The firm made several price target adjustments and
Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
Highlights: Designed to transform clinical trial operations for sponsors, sites and study teams Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial s...
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restric...
Fortrea upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded Fortrea (FTRE) to Buy from Hold with a $15 price target The firm cites the improving macro environment and better company fundamentals for the upgrade. AI concerns
Fortrea price target lowered to $14 from $16 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Fortrea (FTRE) to $14 from $16 and keeps a Hold rating on the shares.
Fortrea price target lowered to $16 from $19 at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on Fortrea (FTRE) to $16 from $19 and keeps an Outperform rating on the shares.
Fortrea price target lowered to $16 from $21 at Citi
Citi lowered the firm’s price target on Fortrea (FTRE) to $16 from $21 and keeps a Buy rating on the shares.
Fortrea price target lowered to $12 from $15 at Barclays
Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $15 and keeps an Equal Weight rating on the shares.
Fortrea Holdings Earnings Call Transcript: Q4 2025
Revenue and Adjusted EBITDA met guidance for 2025, with strong cash flow and cost savings. 2026 guidance anticipates stable revenue, margin improvement, and continued cost optimization, supported by improved biotech funding and operational efficiency.
Fortrea reports Q4 adjusted EPS 9c, consensus 16c
Reports Q4 revenue $660.5M, consensus $665.22M. “We finished 2025 with solid results for the fourth quarter, as the Fortrea (FTRE) team’s shared commitment to commercial, operational and financial exc...
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets
Fortrea appoints Cohen as CMO, Dove as President of CPS
Fortrea (FTRE) announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer, CMO, and president of Clinical Pharmacology Services, CPS, is
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients Adds to executive focus on early clinical development and deepens medical and scientif...
CRO peers lower after Medpace earnings, comments on cancellations
Shares of Contract Research Organizations including Icon plc (ICLR), Fortrea (FTRE) and Charles River Labs (CRL) are trading lower after peer Medpace (MEDP) reported earnings last night and spoke to